Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands

Summary Background Seven-valent pneumococcal conjugate vaccine (PCV7) had profound public-health impacts and is considered cost-effective and potentially cost saving. Two new PCVs have been launched, a 10-valent vaccine (PCV10) and a 13-valent vaccine (PCV13). We examined public-health and economic...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infection 2012-01, Vol.64 (1), p.54-67
Main Authors: Strutton, David R, Farkouh, Raymond A, Earnshaw, Stephanie R, Hwang, Sharon, Theidel, Ulrike, Kontodimas, Stathis, Klok, Rogier, Papanicolaou, Sotiria
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Bacterial diseases
Biological and medical sciences
Child
Child, Preschool
Complications
Cost-Benefit Analysis
Cost-effectiveness
Data processing
Decision-analytic model
Economics
Female
General aspects
Germany
Germany - epidemiology
Greece
Greece - epidemiology
Human bacterial diseases
Humans
Immunization
Infant
Infant, Newborn
Infectious Disease
Infectious diseases
Male
Medical sciences
Middle Aged
Models, Statistical
Mortality
Netherlands
Netherlands - epidemiology
Otitis media
Pediatrics
Pneumococcal conjugate vaccine
Pneumococcal Infections - economics
Pneumococcal Infections - epidemiology
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines - administration & dosage
Pneumococcal Vaccines - economics
Pneumonia
Prevenar
Prevenar 13
Serotypes
Staphylococcal infections, streptococcal infections, pneumococcal infections
Streptococcus pneumoniae
Vaccine
Vaccines
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Seven-valent pneumococcal conjugate vaccine (PCV7) had profound public-health impacts and is considered cost-effective and potentially cost saving. Two new PCVs have been launched, a 10-valent vaccine (PCV10) and a 13-valent vaccine (PCV13). We examined public-health and economic impacts of PCV pediatric national immunization programs (NIPs) in Germany, Greece, and the Netherlands. Methods A decision-analytic model was developed to estimate the impact of PCV13, PCV7, and 10-valent pneumococcal conjugate vaccine (PCV10) on invasive pneumococcal disease (IPD), pneumonia (PNE), and acute otitis media (AOM). Using epidemiological data, we calculated the cases of IPD, PNE, and AOM, using country-specific incidence, serotype coverage, disease sequelae, mortality, vaccine effectiveness, indirect effects, costs, and utilities. Direct effects for PCV13- and PCV10-covered serotypes were assumed similar to PCV7. PCV13 was assumed to confer an indirect effect, while PCV10 was not. Assumptions were tested in sensitivity analyses. Results In a NIP, PCV13 was estimated to eliminate 31.7%, 46.4%, and 33.8% of IPD in Germany, Greece, and the Netherlands, respectively. Compared with PCV7 and PCV10, PCV13 was found to be cost-effective or cost saving in all cases when PCV13 indirect effects were included. Conclusions Pediatric NIPs with PCV13 in Europe are expected to have dramatic public-health impacts and be cost-effective or cost saving.
ISSN:0163-4453
1532-2742
DOI:10.1016/j.jinf.2011.10.015